Sign in

Isabella Camaj

Research Analyst at Evercore ISI

Isabella Camaj is an Equity Research Analyst at Evercore ISI with a focus on technology and industrial sectors, leveraging her expertise to provide in-depth analysis and investment recommendations. She has covered prominent companies in areas such as software, connected operations, and industrial automation, supporting institutional investors with sector-specific insights and quantitative research. Beginning her finance career after graduating from Fordham University, Camaj has developed a strong analytical background, blending her interests in finance, technology, and coding. She holds professional credentials in securities analysis and is recognized for her meticulous and data-driven approach within the equity research community.

Isabella Camaj's questions to ALKAMI TECHNOLOGY (ALKT) leadership

Question · Q2 2025

Isabella Camaj of JPMorgan Chase & Co. inquired about the specific customer types most attracted to the Mantle cross-sell and which products are supporting wins with regional banking customers.

Answer

CEO Alex Shootman explained that the demand for Mantle is broad-based, driven by a universal need for financial institutions to attract low-cost core deposits in the current rate environment. For regional banks specifically, he highlighted the strength of the Mantle onboarding solution, ACH Alert and Positive Pay products, and the ongoing build-out of treasury management capabilities.

Ask follow-up questions

Fintool

Fintool can predict ALKAMI TECHNOLOGY logo ALKT's earnings beat/miss a week before the call

Isabella Camaj's questions to Atea Pharmaceuticals (AVIR) leadership

Question · Q4 2024

Isabella Camaj of Evercore ISI inquired about any specific guidance from the FDA regarding the Phase III trial design and the expected scope of the upcoming Phase II data readout.

Answer

Dr. Janet Hammond, Chief Development Officer, responded that the FDA is fully aligned with Atea's open-label Phase III trial approach and had no substantive comments. Dr. Arantxa Horga, Chief Medical Officer, added that more detailed Phase II data, including safety information, will be presented at a medical meeting in the summer.

Ask follow-up questions

Fintool

Fintool can predict Atea Pharmaceuticals logo AVIR's earnings beat/miss a week before the call